GSK’s Zejula Wins First-Line Ovarian Cancer Use

FDA Extension Is PARP Inhibitor’s Third Indication In That Disease

 
• By Sten Stovall
  
Niraparib_Molecule
Oral, once-daily PARP inhibitor niraparib is being evaluated in multiple pivotal trials. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D